Share on StockTwits

Shares of Novavax (NASDAQ:NVAX) were the target of a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 30,976,672 shares, an increase of 8.3% from the July 31st total of 28,597,396 shares, reports. Currently, 13.9% of the shares of the company are sold short. Based on an average trading volume of 3,439,555 shares, the short-interest ratio is presently 9.0 days.

A number of research firms have recently commented on NVAX. Analysts at Citigroup Inc. initiated coverage on shares of Novavax in a research note on Wednesday, August 13th. They set a “buy” rating and a $9.00 price target on the stock. Analysts at FBR Capital Markets cut their price target on shares of Novavax from $11.00 to $10.00 in a research note on Thursday, August 7th. They now have an “outperform” rating on the stock. Six research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $10.10.

Shares of Novavax (NASDAQ:NVAX) opened at 4.62 on Friday. Novavax has a 52-week low of $2.68 and a 52-week high of $6.95. The stock’s 50-day moving average is $4.46 and its 200-day moving average is $4.71. The company’s market cap is $1.100 billion.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.01. The company had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.74 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. The company’s quarterly revenue was up 134.0% on a year-over-year basis. On average, analysts predict that Novavax will post $-0.28 earnings per share for the current fiscal year.

Novavax, Inc (NASDAQ:NVAX) is a clinical stage biopharmaceutical company.

Receive News & Ratings for Novavax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.